A recently diagnosed HIV-positive patient with a CD4 count of 250 cells/mm³ also tests positive for active tuberculosis. He has not yet been started on ART. What is the correct approach to initiating treatment?

Explanation

## Correct Answer: A. Start ATT first, then initiate ART after 2 weeks In HIV-TB coinfection with CD4 <250 cells/mm³, the sequencing of treatment is critical to prevent immune reconstitution inflammatory syndrome (IRIS) and optimize outcomes. The correct approach is to initiate **anti-tuberculosis therapy (ATT) first**, then start ART after 2 weeks. This 2-week window allows TB treatment to reduce the mycobacterial burden and prevent the paradoxical worsening that occurs when ART-induced immune recovery encounters active TB infection. According to WHO and Indian NTEP guidelines, when CD4 count is <50 cells/mm³, ART should be delayed 2 weeks after ATT initiation; for CD4 50–200 cells/mm³, the delay is also 2 weeks; and for CD4 >200 cells/mm³, ART can start within 2 weeks of TB treatment. This patient's CD4 of 250 cells/mm³ falls into the category where a 2-week delay is appropriate. Starting ATT first ensures TB is being treated while the immune system is still suppressed, reducing the risk of TB-IRIS when CD4 count rises after ART initiation. Early ATT also reduces infectious TB transmission and improves TB treatment outcomes in this vulnerable population. ## Why the other options are wrong **B. Start ATT first, then initiate ART after 8 weeks** — This is wrong because an 8-week delay in ART initiation is excessive and contradicts current Indian NTEP and WHO guidelines. While longer delays were historically used, evidence shows that delaying ART beyond 2 weeks in patients with CD4 <250 cells/mm³ increases mortality risk without additional benefit in preventing IRIS. The 2-week window is the evidence-based standard; 8 weeks unnecessarily prolongs the period of severe immunosuppression and increases opportunistic infection risk. **C. Start both ART and ATT simultaneously** — This is wrong because simultaneous initiation significantly increases the risk of TB-IRIS, particularly with CD4 <250 cells/mm³. When ART rapidly restores immune function while TB bacilli are still abundant, the inflammatory response can cause severe paradoxical worsening of TB manifestations (fever, lymphadenitis, CNS involvement). The 2-week staggered approach allows TB burden reduction before immune reconstitution, substantially lowering IRIS incidence and severity. **D. Start ART first, then begin ATT after 2 weeks** — This is wrong because prioritizing ART over ATT in TB-coinfected patients is contraindicated. TB is an AIDS-defining illness requiring urgent treatment; delaying ATT while starting ART risks TB disease progression, increased transmissibility, and drug-drug interactions that are harder to manage. Indian guidelines mandate ATT initiation first to control the mycobacterial infection before immune reconstitution occurs. ## High-Yield Facts - **CD4 <250 cells/mm³ with active TB**: Start ATT first, then ART after 2 weeks (Indian NTEP guideline). - **TB-IRIS risk** is highest when ART is started simultaneously with TB treatment in severely immunosuppressed patients; staggered initiation reduces paradoxical worsening. - **ATT-ART drug interactions**: Rifampicin induces CYP3A4, reducing protease inhibitor and NNRTI levels; starting ATT first allows optimization of ART regimen choice. - **Mortality benefit**: Initiating ART within 2 weeks of TB treatment (not delaying 8 weeks) in CD4 <50 cells/mm³ reduces 6-month mortality by ~30% (WHO evidence). - **TB is AIDS-defining**: Active TB in HIV requires immediate ATT regardless of CD4 count; ART timing is adjusted based on CD4 level, not TB status. ## Mnemonics **TB-IRIS Prevention: 'TB First, ART Second'** In CD4 <250: Start **TB** treatment first → wait **2 weeks** → then start **ART**. This sequence reduces immune reconstitution inflammatory syndrome (IRIS) by allowing TB bacilli to be cleared before CD4 recovery. Use when deciding treatment order in any HIV-TB coinfection with low CD4. **CD4-Based ART Timing in TB Coinfection** **CD4 <50**: ART at 2 weeks post-ATT. **CD4 50–200**: ART at 2 weeks post-ATT. **CD4 >200**: ART within 2 weeks of ATT start. Remember: lower CD4 = longer wait (but still 2 weeks max), higher CD4 = can overlap sooner. ## NBE Trap NBE may pair "simultaneous initiation" with "faster immune recovery" to lure students who prioritize speed over safety; the trap is forgetting that TB-IRIS mortality and morbidity outweigh the theoretical benefit of early ART in this scenario. Similarly, the "8-week delay" option appeals to students who recall older guidelines but miss the current evidence-based 2-week standard. ## Clinical Pearl In Indian TB-HIV clinics, the "2-week rule" is bedside practice: start ATT immediately (TB is life-threatening), counsel the patient on adherence, optimize nutrition, and schedule ART initiation for day 14–21. This approach has reduced TB-IRIS hospitalizations and improved TB cure rates in Indian cohorts while maintaining low early mortality. _Reference: NTEP (National TB Elimination Programme) Guidelines on TB-HIV Coinfection; WHO Consolidated Guidelines on HIV-TB Coinfection (2019); Harrison's Principles of Internal Medicine Ch. 197 (HIV/AIDS)_